Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010853 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTKCNH2CHRM1 | |
| SCHEMBL5535946 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTKCNH2CHRM1 | |
| SCHEMBL5540324 | 0.85 | CHRM1 (0.35) | ALDH1A1LMNAKCNH2CHRM1 | |
| SCHEMBL5538961 | 0.85 | CHRM1 (0.35) | ALDH1A1LMNAKCNH2CHRM1 | |
| SCHEMBL5538952 | 0.85 | CHRM1 (0.35) | ALDH1A1LMNAKCNH2CHRM1 | |
| SCHEMBL3466776 | 0.84 | GRM2 (0.41) | ALDH1A1LMNAMAPTKCNH2CHRM1 | |
| SCHEMBL6010744 | 0.80 | CHRM1 (0.44) | ALDH1A1MAPTKCNH2CHRM1 | |
| SCHEMBL5542598 | 0.80 | CHRM1 (0.44) | ALDH1A1MAPTKCNH2CHRM1 | |
| SCHEMBL3466812 | 0.79 | CHRM1 (0.50) | ALDH1A1LMNAMAPTKCNH2CHRM1 | |
| SCHEMBL3465898 | 0.79 | CHRM1 (0.50) | ALDH1A1LMNAMAPTKCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885LMNA 4152/4885MAPT 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.